HC Wainwright Has Lowered Expectations for Imunon (NASDAQ:IMNN) Stock Price

Imunon (NASDAQ:IMNN) had its price target lowered by HC Wainwright from $14.00 to $12.00 in a research note published on Monday,Benzinga reports. The firm currently has a buy rating on the stock.

Separately, EF Hutton Acquisition Co. I raised shares of Imunon to a “strong-buy” rating in a research report on Monday, September 23rd.

Imunon Price Performance

Shares of Imunon stock opened at $0.75 on Monday. The firm has a market cap of $44.92 million, a PE ratio of -0.40 and a beta of 2.14. Imunon has a 52 week low of $0.48 and a 52 week high of $3.65. The business’s fifty day simple moving average is $0.99 and its 200-day simple moving average is $1.18.

Imunon (NASDAQ:IMNN) last announced its earnings results on Wednesday, August 14th. The company reported ($0.51) earnings per share for the quarter, topping the consensus estimate of ($0.55) by $0.04. As a group, equities analysts expect that Imunon will post -1.68 earnings per share for the current year.

About Imunon

Imunon, Inc, a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company’s lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development.